Skip to content
Open access

Circulating Microbial DNA as a Potential Cancer Biomarker: Technical Challenges and Controlled Evaluation

Aug 2026 · bioRxiv · 0 citations · 17 references
Biology

TL;DR

Much of the apparent cmDNA structure, including its agreement with a published cancer-microbiome catalog, is explained by base composition and reference-database architecture rather than authentic biology, and short-read k-mer pipelines cannot separate the two on their own.

Abstract

Background Circulating microbial DNA (cmDNA) has been proposed as a non-invasive cancer biomarker, but most evidence comes from cancer-sequencing datasets not designed for microbial analysis and lacking contamination controls. Whether reported signatures reflect biology or artifact is unclear in low-biomass specimens, where standard taxonomic pipelines are prone to systematic error. Methods In a tightly controlled pilot study of metastatic castration-resistant prostate cancer, we profiled plasma cell-free DNA (cfDNA) and buffy-coat genomic DNA (gDNA) from two patients and two healthy volunteers alongside mock blood-draw and reagent controls, each with and without host-DNA depletion. Reads were classified with Kraken2/Bracken and, independently, with the marker-gene classifier MetaPhlAn. As informatics controls, reads were per-base shuffled to randomize nucleotide order while preserving read length and guanine-cytosine (GC) content, and purely synthetic reads were generated from a four-base process matched only to an aggregate GC target; both were classified identically. Genus abundances were regressed against Kraken2 database k-mer representation and against GC content. Results Across 40 samples, Kraken2 reported several thousand genera, samples clustered by specimen type in principal-coordinate analysis (PCoA), and pooled genus counts correlated strongly with a published cancer-microbiome catalog (The Cancer Genome Atlas lung adenocarcinoma, TCGA-LUAD; Spearman ρ = 0.81 over 282 shared genera), a pattern readily interpreted as biological signal. However, these observations were also made in per-base shuffling, which preserves GC content and length but destroys all biological sequence: shuffled reads were still abundantly classified, still clustered by specimen type, and still correlated with the catalog (ρ ≈ 0.7), as did every sample group, including pure reagent controls. Genus counts scaled tightly with each genus’s k-mer representation in the Kraken2 database on real (r² = 0.74) and shuffled (r² = 0.85) reads, and the same dependence appeared in the independent published cohort. Purely synthetic reads carrying no information beyond an aggregate GC target reproduced much of the cross-cohort agreement (synthetic TCGA-LUAD ρ = 0.61 versus 0.81 for real reads; significant in 27 of 33 TCGA cancers), and replicate shuffles of a low-GC versus a high-GC plasma sample, for which the true difference is zero, produced spurious significant differences in about 46% of genera. Regressing observed counts against the shuffled baseline left 23 genera above the artifact floor at 5% false discovery rate (FDR), nearly all known kit contaminants, control-enriched viruses, or very-low-abundance taxa; a four-criterion validity filter reduced thousands of Kraken2 genera to a single defensible candidate, Klebsiella. Conclusions Much of the apparent cmDNA structure, including its agreement with a published cancer-microbiome catalog, is explained by base composition and reference-database architecture rather than authentic biology, and short-read k-mer pipelines cannot separate the two on their own. We find little positive evidence of an authentic circulating microbial signal, though our small sample cannot prove its absence. To limit false discovery in low-biomass metagenomics, we recommend specimen-matched negative controls, corroboration with a conservative second classifier, per-base shuffling (with GC-matched synthetic reads as a stricter floor), and GC-aware analysis. Graphical Abstract Pipeline pitfalls in blood microbial-DNA assays. cmDNA from low-biomass blood is vulnerable to three errors across the workflow (collection, processing, library preparation and sequencing, informatics): environmental (non-blood) contamination, kit and reagent contamination, and taxonomic misclassification. The corresponding safeguards are mock and specimen-matched negative controls, a literature sweep for known contaminants, and corroboration of k-mer output with a marker-gene classifier and a shuffle-based artifact control.

Read PDF

Similar papers

Open access Aug 2026

Metagenomic profiling of blood-associated microbial DNA signatures in leukemia-associated febrile neutropenia

Febrile neutropenia (FN) is a life-threatening complication of chemotherapy, but the low microbial biomass of blood makes shotgun metagenomic profiles highly sensitive to technical background. We reanalyzed 47 publicly available patient sequencing runs representing 43 unique patient-timepoint samples from 19 SRA-labeled patients, together with 23 no-template-control (NTC) runs spanning 21 sequencing batches. To distinguish reference-catalogue content from progressively stronger evidence of patient-associated signal, we applied batch-matched NTC correction together with nested abundance thresholds and a feature-specific global NTC envelope. CheckM2 evaluated 1,013 bins; 13 met completeness ≥50% and contamination <10%, and dereplication yielded 11 draft MAG representatives. Ten representatives showed positive patient-to-control abundance excess, but only four showed recurrent support above both threefold matched-control abundance and the global NTC envelope. Functional annotations were therefore interpreted as reference-genome homologs rather than evidence of expression, phenotype, viability or bloodstream origin. Matched-control correction retained 19 read-level ARG types, but only seven subjects contributed complete longitudinal ARG-profile contrasts, limiting reliable temporal inference. The resulting run-resolved, nested evidence framework identified a subset of microbial DNA and ARG signals that remained detectable under increasingly stringent control criteria while distinguishing them from catalogue-level or background-sensitive signals. These findings support cautious reporting of patient-enriched microbial DNA and ARG signals rather than inference of a resident blood microbiome or clinical resistance phenotype.

Ming Zhang, Lan He, Huaping Xin et al. · 0 citations
Open access Aug 2026

Circulating blood microbiome biomarkers as liquid biopsy in breast cancer

Circulating tumor material can already be used to help in cancer management, but host–microbiota interactions may add complementary value. This study evaluated a “liquid microbiopsy”, combining cell-free microbial DNA (cf-mbDNA) with host biomarkers of microbial translocation/permeability (LBP, sCD14, I-FABP), to refine staging and prognosis in breast cancer. We analyzed 136 individuals: 58 metastatic breast cancer (MBC), 58 early breast cancer (EBC), and 20 healthy donors. Plasma cf-mbDNA was quantified by 16S rRNA qPCR with extraction/run negative controls; LBP, sCD14, I-FABP by ELISA; and CRP by immunoturbidimetry. Circulating tumor cells (CTCs) and PD-L1 on CTCs were assessed by CellSearch® and immunostaining. Diagnostic performance was assessed by area under the ROC curve. In MBC, progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox models. LBP discriminated EBC from MBC with an AUC 0.92, with a slight improvement in the 3- or 5-marker models (AUC 0.936–0.939). For EBC vs healthy donors, CRP showed modest performance (AUC 0.73), and marker combinations offered no improvement.. In MBC (median follow-up 77.5 months), median PFS and OS were 4.5 and 14.5 months, respectively. In univariate analysis, shorter PFS was associated with tumor subtype, > 3 prior treatments, > 2 metastatic sites, CTCs ≥ 5, and PD-L1–positive CTCs detection. In multivariate analysis, sCD14 and I-FABP independently predicted PFS, while sCD14 was independently associated with OS. A measurable host–microbiota–barrier axis (LBP, sCD14, I-FABP) provided stage-related and prognostic information complementary to CTC/PD-L1 status, whereas cf-mbDNA load alone showed limited discriminative value. These findings support liquid microbiopsy as a complementary extension of liquid biopsy but must be considered as exploratory, and warrant multicenter validation in larger independent cohorts with standardized pre-analytics and low-biomass controls. NCT03449264; NCT02866149.

W. Jacot, L. Cayrefourcq, C. Dunyach-Rémy et al. · 0 citations
Review Open access Jul 2026

Non-Coding RNAs in Cancer Liquid Biopsy: From Regulatory Networks to Functional Biomarkers for Precision Oncology

Liquid biopsy is now an established component of precision oncology, and its clinical implementation to date has been led by cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) assays. These assays report genomic alterations, yet they may be limited by low tumor fraction, reduced shedding in early disease, and incomplete representation of dynamic tumor biology. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and emerging small or poorly annotated RNA species, provide a complementary layer because they can reflect regulatory programs, tissue injury, immune modulation, metastatic communication, and therapeutic pressure. This review explores circulating and extracellular vesicle (EV)-associated ncRNAs as functional readouts in cancer liquid biopsy. We discuss their biological origin, carrier state, biofluid context, clinical applications, analytical technologies, artificial intelligence (AI)-assisted integration, standardization barriers, and regulatory requirements. The technology discussion considers sequencing, targeted amplification, and emerging direct or polymerase chain reaction (PCR)-free strategies as complementary translational routes for reliable ncRNA measurement. We propose that ncRNAs should not be viewed as alternatives to ctDNA, but as potential functional biomarkers that can link tumor genotype, regulatory state, and clinical phenotype within integrated multi-analyte precision oncology.

Salvatore Pernagallo, Veronica Tisato, Donato Gemmati · 0 citations
Review Open access Sep 2026

Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making

Breast cancer remains the most frequently diagnosed cancer and a leading cause of cancer-related mortality among women worldwide, underscoring the need for accurate, minimally invasive biomarkers to support precision oncology. Conventional tissue biopsy remains the standard for molecular characterization but is limited by its invasiveness, inability to capture spatial and temporal tumor heterogeneity, and challenges in serial monitoring. Circulating tumor DNA (ctDNA), a tumor-derived fraction of cell-free DNA, has emerged as a promising liquid biopsy biomarker capable of providing real-time genomic information throughout disease progression. This narrative review examines recent advances in ctDNA biology, analytical technologies, clinical applications, current limitations, and future directions in breast cancer management. A structured literature search of PubMed/MEDLINE, Scopus, Embase, Web of Science, and Google Scholar identified relevant English-language publications from 2015 to 2026. Current evidence indicates that highly sensitive platforms, including digital PCR, BEAMing, and next-generation sequencing, can detect clinically actionable alterations in genes such as PIK3CA, ESR1, TP53, ERBB2, AKT1, and BRCA1/2. ctDNA has demonstrated particular utility in identifying minimal residual disease, monitoring therapeutic response, detecting emerging resistance mechanisms, and guiding targeted treatment selection in advanced breast cancer. However, applications in early cancer detection, population screening, and artificial intelligence-assisted clinical decision-making remain investigational. Widespread clinical implementation is constrained by low ctDNA abundance in early-stage disease, analytical variability, limited assay standardization, and cost considerations. Continued technological innovation, prospective multicenter validation, standardized testing protocols, and evidence-based clinical guidelines are essential to fully integrate ctDNA into routine precision breast cancer care.

Unknown authors · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.